#USA #Thousand Oaks #Ezetimibe #Repatha #Evolocumab

New Study Reveals Repatha® Effectively Reduces Heart Attack Risks

In a comprehensive real-world study, Amgen recently announced that its drug Repatha® (evolocumab) significantly lowers the risk of both fatal and nonfatal heart attacks. The research, which examined over 544,000 adults with atherosclerotic cardiovascular disease (ASCVD) who were previously treated with statins, found a notable 20% reduction in heart attack risks for those taking Repatha compared to those on ezetimibe.

This study stands as one of the most extensive and rigorous analyses of head-to-head outcomes involving Repatha and ezetimibe, which is commonly prescribed for lowering LDL cholesterol. The findings, published in The American Journal of Preventive Cardiology, emphasize the need for effective treatment options for patients struggling to reach recommended cholesterol levels using statins alone. Dr. Paul Burton, the chief medical officer at Amgen, highlighted that many patients cannot achieve desired LDL-C levels with statin therapy, making new treatment options like Repatha essential for clinical practice.

Understanding Repatha's Role

Repatha is an antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL cholesterol from the bloodstream. By binding to PCSK9, Repatha increases the number of LDL receptors available, allowing more LDL to be cleared from the blood. This mechanism significantly enhances LDL-C reduction, coupled with the impressive clinical evidence that supports Repatha's efficacy.

Study Details and Findings

The study focused on a cohort that included patients who began either Repatha or ezetimibe therapy between 2017 and 2024, with follow-up data available through June 2026. Among those with initial LDL cholesterol measurements, the cumulative four-year risk of heart attack was much lower in the Repatha group (5.88%) than in the ezetimibe group (7.76%). For patients without baseline LDL-C measurements, the four-year risks were also significantly different, showcasing the robust performance of Repatha.

Amgen utilized a thorough analytical methodology which included inverse probability weighting to balance treatment groups concerning various baseline characteristics, ensuring the reliability of the results. This careful design mirrors that of randomized clinical trials and provides significant real-world data that can guide clinical decision-making.

Implications for Clinical Practice

Dr. Nihar Desai, an associate professor at Yale University School of Medicine, noted the importance of these findings in informing treatment decisions. Two classes of drugs, ezetimibe and PCSK9 inhibitors like Repatha, are now recognized as valid non-statin options for managing patients with ASCVD. However, direct evidence comparing cardiovascular outcomes has been lacking until now, making this study a pivotal contribution to clinical guidelines and patient care strategy.

Amgen's Commitment to Cardiovascular Health

As cardiovascular disease continues to pose a significant global health burden, Amgen is dedicated to innovating treatment strategies that tackle multiple interrelated risk factors affecting heart health. Their research and clinical studies aim to enhance the prevention and management of cardiovascular diseases through advanced treatment pipelines, grounded in scientific innovation and patient care improvements.

Conclusion

The latest findings from Amgen's study provide vital evidence that Repatha — a medication used by millions globally — not only effectively manages cholesterol but also significantly reduces the risk of heart attacks compared to ezetimibe. Patients and healthcare providers can draw from these insights to make more informed choices regarding cardiovascular risk management, which is crucial in today's increasingly challenging health landscape. With Amgen's continuing commitment to research and cardiovascular innovation, the path forward appears promising for those affected by heart disease.